Evidence map›Paper›PMID 40978503›Full record

ReviewFrontiers in drug safety and regulation2025

Corticosteroids in lung cancer.

Vesna Ćeriman Krstić, Milija Gajić, Leonida Djukanović, Dragana Jovanović

Abstract readReview
In one paragraph

Review in Frontiers in drug safety and regulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vesna Ćeriman KrstićFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Milija GajićClinic for Pulmonology, University Clinical Center of Serbia, Belgrade, Serbia.
Leonida DjukanovićMunicipal Institute for Lung Diseases and TB, Belgrade, Serbia.
Dragana JovanovićInternal Medicine Clinic, "Akta Medica", Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite significant advances in lung cancer treatment, patients with this disease still present with multiple symptoms that are very hard to control. Corticosteroids are widely used in patients with lung cancer, but without clear evidence for their efficacy. Thus, corticosteroids have been used for the treatment of conditions arising due to the tumor itself, adverse effects of the applied specific therapy and symptom palliation. In this review we are going to summarize clinical indications for corticosteroid use in patients with lung cancer: malignant airway obstruction, superior vena cava syndrome, brain metastases, treatment-related adverse events, anorexia and cachexia, fatigue, dyspnea, nausea and vomiting, spinal cord compression, and pain.

Indexed as

brain metastasescachexiacorticosteroidsdyspneaimmunotherapylung cancernausea and vomitingpain

Identifiers

PMID40978503
PMCPMC12443125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.